Vacular disease, including heart attack and stroke, are major causes of death and illness in patients with diabetes. This long term goal of this application is to identify novel strategies to reduce vascular disease in diabetes. The balanced production of reactive nitrogen and oxygen species plays a critical role in the regulation of normal vascular function. Diabetes increases oxidative stress in vascular wall cells leading to reduced nitric oxide (NO) bioavailability and endothelial dysfunction. This proposal explores the novel hypothesis that the ligand-activated transcription factor, peroxisome proliferator-activated receptor gamma (PPARg) controls a program of gene expression in vascular endothelium that regulates the balance between the production of reactive nitrogen and oxygen species and that PPARg stimulation exerts vascular protective effects in vivo by directly stimulating endothelial PPARg to increase NO bioavailability. The PI has demonstrated that direct activation of vascular endothelial cell PPARg with thiazolidinediones increased endothelial cell NO release and reduced superoxide production.
Aim 1 will examine mechanisms by which PPARg alters endothelial superoxide metabolism in vitro and in vivo. Preliminary data indicate that PPARg activation decreases the enhanced expression and activity of NADPH oxidase in the vascular wall of diabetic animals and attenuates vascular dysfunction.
Aim 2 will define the impact of PPARg activation on post- translational mechanisms regulating eNOS activity in vitro and in vivo. Because PPARg ligands do not increase the expression of endothelial nitric oxide synthase (eNOS), this aim will focus on PPARg-mediated alterations in the post-translational regulation of eNOS activity including eNOS-protein interactions and site-specific eNOS phosphorylation events.
Aim 3 will determine basal and thiazolidinedione-stimulated vascular endothelial function in normal and diabetic endothelial-specific PPARg null mice. These innovative studies will clarify the vascular consequences of reduced endothelial PPARg function and permit analysis of specific effects of endothelial PPARg activity in vascular function. This proposal will clarify roles of PPARg in vascular regulation in diabetes and contribute to the development of improved strategies for the prevention and treatment of vascular disease associated with impaired endothelial NO production.

Public Health Relevance

Diabetes and obesity are increasing at alarming rates in the United States. Vascular disease associated with diabetes is a major cause of morbidity and mortality in these patients. This proposal will explore a novel role for the PPAR gamma receptor in diabetic vascular disease and define if stimulating this receptor with currently available drugs leads to improved vascular outcomes in diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK074518-05
Application #
8197197
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Jones, Teresa L Z
Project Start
2008-01-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2013-11-30
Support Year
5
Fiscal Year
2012
Total Cost
$268,878
Indirect Cost
$60,607
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Wongtrakool, Cherry; Grooms, Kora; Bijli, Kaiser M et al. (2014) Nicotine stimulates nerve growth factor in lung fibroblasts through an NF?B-dependent mechanism. PLoS One 9:e109602
Lu, Xianghuai; Bijli, Kaiser M; Ramirez, Allan et al. (2013) Hypoxia downregulates PPARýý via an ERK1/2-NF-*B-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells. Free Radic Biol Med 63:151-60
Sutliff, Roy L; Hilenski, Lula L; Amanso, Angelica M et al. (2013) Polymerase delta interacting protein 2 sustains vascular structure and function. Arterioscler Thromb Vasc Biol 33:2154-61
Green, David E; Sutliff, Roy L; Hart, C Michael (2011) Is peroxisome proliferator-activated receptor gamma (PPARýý) a therapeutic target for the treatment of pulmonary hypertension? Pulm Circ 1:33-47
Kang, Bum-Yong; Kleinhenz, Jennifer M; Murphy, Tamara C et al. (2011) The PPAR? ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 301:L881-91
Blanquicett, Carmelo; Kang, Bum-Yong; Ritzenthaler, Jeffrey D et al. (2010) Oxidative stress modulates PPAR gamma in vascular endothelial cells. Free Radic Biol Med 48:1618-25
Sutliff, Roy L; Kang, Bum-Yong; Hart, C Michael (2010) PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis 4:143-60
Lu, Xianghuai; Murphy, Tamara C; Nanes, Mark S et al. (2010) PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B. Am J Physiol Lung Cell Mol Physiol 299:L559-66
Kleinhenz, Jennifer M; Kleinhenz, Dean J; You, Shaojin et al. (2009) Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 297:H1647-54
Nisbet, Rachel E; Graves, Anitra S; Kleinhenz, Dean J et al. (2009) The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol 40:601-9